Literature DB >> 3944752

Ligation of the patent ductus arteriosus in newborn respiratory failure.

C Hubbard, R W Rucker, F Realyvasquez, D R Sperling, D A Hicks, C C Worcester, R Amlie, R F Huxtable, R H Bartlett, A B Gazzaniga.   

Abstract

Patent ductus arteriosus (PDA) is commonly associated with respiratory disease in newborn infants and may require ligation. Surgical ligation of the PDA can be done in small infants with low operative risk and minimal complications. The outcome of patients after ligation depends primarily on the severity of the underlying pulmonary disease. One hundred fifty-one patients have undergone ligation in an eight-year period at this center. A simplified technique performed in the neonatal intensive care unit with the use of local anesthesia and conventional ventilator management is described.

Entities:  

Mesh:

Year:  1986        PMID: 3944752     DOI: 10.1016/s0022-3468(86)80639-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  In-situ emergency pediatric surgery in the intensive care unit.

Authors:  A Ghallab; Y El-Gohary; M Redmond; M Corbally
Journal:  Ir J Med Sci       Date:  2012-04-20       Impact factor: 1.568

2.  Extracorporeal life support for neonatal respiratory failure. A 20-year experience.

Authors:  C J Shanley; R B Hirschl; R E Schumacher; M C Overbeck; T N Delosh; R A Chapman; A G Coran; R H Bartlett
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

3.  Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis.

Authors:  Lleona C L Lee; Angela Tillett; Robert Tulloh; Robert Yates; Wilf Kelsall
Journal:  BMC Pediatr       Date:  2006-05-11       Impact factor: 2.125

4.  Surgical procedures performed in the neonatal intensive care unit on critically ill neonates: feasibility and safety.

Authors:  Mohammad Saquib Mallick; Abdul Monem Jado; Abdul Rahman Al-Bassam
Journal:  Ann Saudi Med       Date:  2008 Mar-Apr       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.